On September 6, 2024 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, reported that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors (Press release, Xencor, SEP 6, 2024, View Source [SID1234646395]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast may be accessed through "Events & Presentations" in the Investors section of the Company’s website, located at investors.xencor.com. Telephone participants may register to receive a dial-in number and unique passcode that can be used to access the conference call. A recording will be available for at least 30 days.

On September 6, 2024 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, reported that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference, which is taking place September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY (Press release, Oncolytics Biotech, SEP 6, 2024, View Source [SID1234646394]). Chief Medical Officer Tom Heineman, M.D., Ph.D., will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference, which is taking place September 17-19, 2024 at the InterContinental New York Barclay Hotel in New York, NY. Additional details on the fireside chats can be found below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 26th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Time: 9:00 a.m. ET
Location: Lotte New York Palace Hotel, Holmes I Room – 4th Floor
Webcast Link: Available by clicking here

Event: Cantor 2024 Global Healthcare Conference
Date: Thursday, September 19, 2024
Time: 10:55 a.m. ET
Location: InterContinental New York Barclay Hotel, Track 6 Morgan Suite
Webcast Link: Available by clicking here

Company management will also be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or Cantor Fitzgerald representative, or email [email protected].

Webcasts of the Company’s presentations will also be available on the Investor Relations page of Oncolytics’ website (LINK) and will be archived for three months.

On September 6, 2024 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, reported that updated clinical data on its lead cell therapy candidate, ACTengine IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research (Press release, Immatics, SEP 6, 2024, View Source [SID1234646393]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentation

Date / Time: October 11, 2024 / 8:00 – 8:20 am Central Daylight Time
Session: Plenary Session 1 – Developmental Immunotherapy (Cellular Immunotherapy, Vaccines, and New Checkpoints)
Title: ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma – Clinical Update
Presenter: Martin Wermke, M.D. (University Hospital Dresden, Germany)

About IMA203

ACTengine IMA203 T cells is an autologous T cell product with a genetically modified, pairing-enhanced TCR directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). This peptide is frequently expressed in a large variety of solid cancers, thereby supporting the program’s potential to address a broad cancer patient population. Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics’ proprietary mass spectrometry-based target discovery platform, XPRESIDENT. Through its proprietary TCR discovery and engineering platform XCEPTOR, Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine IMA203.

ACTengine IMA203 TCR-T is currently being evaluated in a Phase 1 trial as IMA203 monotherapy, and as a second-generation IMA203CD8 (GEN2) monotherapy, where IMA203-engineered T cells are co-transduced with a CD8αβ co-receptor, thereby leveraging the power of both CD4+ and CD8+ T cells. As previously reported, IMA203 in combination with an immune checkpoint inhibitor has been deprioritized.

On September 5, 2024 HanX Biopharmaceuticals reported that the first Phase 2 clinical trial of HX009 in combination therapy received approval from the National Medical Products Administration (NMPA) (Press release, HanX Biopharmaceuticals, SEP 5, 2024, View Source [SID1234655961]). This application, which met the relevant drug registration requirements, approved the Phase 2 clinical trial of HX009 in combination therapy for biliary tract cancer (BTC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HX009 is a clinical-stage investigational anti-PD-1 and anti-CD47 bifunctional large molecule cancer immunotherapy independently developed by Hans-Itai. Two Phase I single-agent dose-escalation trials in solid tumors have been successfully completed in Australia and China. Phase I monotherapy data demonstrated a favorable safety and tolerability profile, with single-agent anti-tumor efficacy observed in multiple indications, including biliary tract malignancies. Existing data support advancement into Phase II and combination trials. The company currently plans to conduct multicenter Phase II trials in multiple clinical indications.

Dr. Lei Zhang, Chief Medical Officer of Hans Ait, said: "We are very pleased that HX009 has received its first clinical approval for combination use from the National Medical Products Administration. Although the application of immunotherapy (including PD-1/PD-L/CTLA4 antibodies, etc.) has improved the survival prognosis of BTC patients to a certain extent, some patients still lack response to immunotherapy and suffer from immunotherapy resistance. In the Phase I clinical trial, we have observed that HX009 monotherapy can induce objective remission of biliary tract malignancies, suggesting the therapeutic potential of HX009 in this indication. We look forward to rapidly advancing this clinical trial and providing new treatment options for patients as soon as possible."

On September 5, 2024 Genetic Leap, an AI-native techbio company innovating at the cutting edge of Artificial Intelligence and RNA genetic medicine, reported a research collaboration with Eli Lilly and Company to develop genetic medicine therapeutics (Press release, Genetic Leap, SEP 5, 2024, View Source [SID1234654445]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration builds on a successful pilot between the two companies and will leverage Genetic Leap’s RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas. The central role of RNA in orchestrating essential biological processes holds significant potential to address critical diseases that traditional drugs have not been able to target effectively. Historically, drugging RNA has presented tremendous challenges. Genetic Leap’s proprietary AI platform is revolutionizing the approach to drugging RNA.

"We are thrilled to collaborate with Lilly and deeply share their strong commitment to developing RNA medicines," said Dr. Bertrand Adanve, CEO and founder of Genetic Leap. "Our primary goal in building the Genetic Leap AI platform is to accelerate the development of life-saving medicines for patients, and this collaboration with Lilly’s talented and savvy R&D team takes us significantly closer to that goal."

Under the terms of the agreement, Genetic Leap will receive from Lilly up to $409 million in upfront, development, clinical, regulatory, and commercial milestone payments, in addition to tiered royalties.